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Abstract
Background demented patients have been reported to be healthier than other old people of the same age.
Objectives to assess comorbid conditions, functional and nutritional status in medically ill hospitalised patients with normal
cognition or affected by dementia of various causes and severities, or mild cognitive impairment (MCI).
Design and Setting a prospective study was carried out, between January and December 2004, in the Rehabilitation and
Geriatric Hospital (HOGER).
Methods activities of daily living (ADL), instrumental activities of daily living (IADL) and mini nutritional assessment (MNA)
scores were assessed as a function of the status of the patient two weeks before admission to hospital. On admission, cognitive
status was assessed by a systematic battery of neuropsychological tests, comorbid conditions were assessed with the Charlson
comorbidity index (CCI), and body mass index (BMI) and functional independence measure (FIM) were determined. BMI
and FIM were also determined on discharge.
Results we studied 349 patients (mean age 85.2 ± 6.7; 76% women): 161 (46.1%) cognitively normal, 37 (10.6%) with MCI
and 151 (43.3%) demented (61 Alzheimer’s disease (AD), 62 mixed dementia (MD) and 17 vascular dementia (VaD)). ADL,
IADL, FIM and MNA scores on admission decreased with cognitive status, regardless of the type of dementia. Functionality
at discharge remained significantly lower in demented patients than in other patients. CCI was high and similar in all
three groups (mean 4.6 ± 2.7). Patients with VaD had poorer health than other demented patients, with a higher average
comorbidity score, more frequent hypertension, stroke and hyperlipidaemia. Comorbidity did not increase with severity levels
of dementia.
Conclusions in this cohort of very old inpatients, demented patients, non-demented patients and patients with MCI had
similar levels of comorbidity, but demented patients had a poorer functional and nutritional status.
Keywords: comorbidity, dementia, Alzheimer’s disease, aged, elderly
Introduction
Demented patients have been reported to be healthier than
other old people [1–5]. Comparisons of the various subtypes
of dementia have shown that patients with Alzheimer’s
disease (AD) are the healthiest [2, 4, 6]. However, these
findings could be a consequence of inaccurate symptom
reporting, delaying diagnosis, or may reflect a failure on the
part of screening strategies to investigate thoroughly and to
diagnose disease in these patients [1, 7]. This would suggest
that demented patients may present more medical illnesses
than generally thought, but that these diseases remain
undetected [5, 8]. A few series of autopsies have confirmed
this hypothesis, showing that demented patients often
have a number of comorbid conditions that are frequently
underestimated by clinicians [9, 10]. The studies investigating
these issues were carried out retrospectively [1–3, 5, 6, 11];
cognitive assessment was based only on the Mini Mental
State Examination (MMSE) [1, 2, 8, 12] and/or populations
of community-dwelling subjects at least 10 years younger
than patients from geriatric wards [7, 8, 11]. We carried out
a prospective study in the Geriatric Hospital (HOGER),
including the systematic assessment of comorbid conditions
and cognitive, functional andnutritional status.We compared
these correlates in cognitively normal and demented patients.
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Methods
Study population
A prospective study was carried out in the Geriatric Hospital
(HOGER) of the Geneva University. Patients were recruited
by clinically trained staff. The sampling frame consisted
of consecutive admissions of patients over 75 years of
age, on selected days during 2004. A random sample of
patients was selected each day, using a computer-generated
randomisation table. The exclusion criteria were disorders
interfering with psychometric assessment, terminal illness
and residence outside the canton of Geneva. The local ethics
committees approved the study protocol, and signed written
informed consent was obtained from all patients or their
families or legal representatives. We checked that the study
sample was representative of the hospital population as a
whole, by comparing demographic data for the included
sample with data for all admitted patients, and for those
who refused to participate. We checked for selection bias
based on cognitive screening for patients who refused to
participate.
The study protocol included a planned 4-year follow-
up period, with an annual visit carried out by the same
geriatrician and nurse team.
Measures
Socio-demographic data and pre-morbid functional status.
The data recorded included age, sex, native language,
education level, marital status, living conditions, alcohol and
nicotine consumption. Basic and instrumental activities of
daily living (IADL/ADL) [13, 14] were determined by the
same nursing team on the admission day of the patient
(please see Appendix 1 in the supplementary data on the
journal website (http://www.ageing.oupjournals.org/)). The
information regarding the previous 2 weeks was supplied by
the patient when he was capable of answering and by an
informal and/or formal caregiver.
Cognitive assessment
The same neuropsychologist assessed all subjects at
least one week after patient inclusion. The following
neuropsychological battery was applied: the MMSE [12]
and the short cognitive evaluation [15, 16] (Appendix
2). The short version of the geriatric scale was used
to screen for depression [17]. Based on this screening,
a comprehensive standardised neuropsychological battery
used in our routine clinical practice was carried out by
the same neuropsychologist, with formal clinical criteria
used to determine the aetiology and severity of clinical
dementia (Appendix 3). Cerebral imaging was also carried
out. Thereafter, patients were assigned to three groups:
(i) cognitively normal, (ii) patients with mild cognitive
impairment (MCI) [18] and (iii) patients with various types
of dementia.
Comorbidity
The Charlson Comorbidity Index (CCI) was determined
by extensive review of the patient’s medical records
for diagnoses established at/or before enrolment in this
study [19], higher scores indicating greater comorbidity. The
various classes of medication taken before admission were
also listed.
Functionality
The functional independence measure (FIM) scores range
from 18 (completely dependent) to 126 (completely
independent) (Appendix 4) [20]. The FIM was determined
in the first three days after admission and at discharge.
Nutritional assessment
Bodymass index (BMI) was estimated (kg/m2) on admission
and at discharge. The short version of the mini nutritional
assessment (MNA) (MNA-15, score ranging from 0 to
14, ≥ 12 = normal) was evaluated on admission of the
patient [21]. The reference period for the MNA was 2 weeks
before admission.
Statistical methods
We checked the normality of the data distribution with
skewness and kurtosis tests, and carried out standard
transformations to normalise non-Gaussian variables. Data
for continuous variables are presented as means±1 standard
deviation (SD).
Mann–Whitney U tests were used to compare data
between groups: the studied sample versus all hospitalised
patients, or the studied sample versus patients who refused
to participate.
Analysis of variance (ANOVA) or Kruskal–Wallis tests
were performed to compare data between the following
groups: (i) the studied sample, patients refusing to participate
and patients excluded from the study; (ii) cognitively
normal patients, patients with MCI and demented patients;
(iii) patients affected with dementia of various aetiologies.
Statistical analyses were performed with Stata version
9.2.1 [22].
Results
Of the 459 patients randomised, 49 were not eligible (10.7%):
20 hadmajor behavioural problems (psychotic, suicidal), nine
were unable to communicate, eight were terminally ill, seven
lived outside the canton of Geneva, and no family or legal
representative could be contacted for five patients. Of the
410 patients who met the eligibility criteria, 61 (14.9%)
refused to participate (the patient in 58 cases and the family
in 3 cases). Our analysis was therefore based on a cohort of
349 patients.
No differences in demographic characteristics were found
between the study sample and the entire population of
patients admitted to the HOGER during 2004, or between
the study sample and excluded patients or patients who
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refused to participate (Table 1). Functionality scores were
similar in the study cohort and in the patients who refused
to participate. The functionality scores of both these groups
were slightly higher than those for the entire population of
patients admitted to the hospital, but were significantly lower
for the excluded group.
In total, 151 of the 349 patients (43.3%) were diagnosed
as demented and 37 (10.6%) were found to have MCI.
Table 2 summarises the demographic and pre-admission
characteristics of the patients, and assessment data on
admission and discharge as a function of cognitive status. The
groups compared were similar in age, sex, education level,
smoking habits and alcohol intake. However, they differed
in terms of living conditions, with non-demented patients
more likely to live alone, and demented patients more likely
to live in a nursing home (P = 0.005). Pre-morbid ADL
and IADL scores, and FIM and MNA scores on admission
decreased with cognitive status. At discharge, functionality
scores remained lower for demented patients than for the
other two groups. A similar trend was observed for BMI,
which was lower at admission in demented patients, although
this trendwas not statistically significant at discharge. Patients
with MCI had better scores than demented patients but
worse scores than non-demented patients, except for FIM at
discharge, whichwas highest for theMCI group. The number
of different classes of medication taken was significantly
higher in demented patients than in the other two groups,
with non-demented andMCI patients taking similar numbers
of drugs. CCI was similar in all three groups, with demented
patients having levels of comorbidity similar to those for the
non-demented and MCI groups. The CCI assesses several
different diseases. For these diseases, demented patients were
found to be significantly more likely than the patients in the
other two groups to suffer from cerebrovascular disease and
stroke. For diseases not assessed in the CCI, hypertension
was found to be more prevalent in non-demented than in
demented patients.
We determined the type of dementia for the 151 patients
diagnosed as demented: 61 were classified as having AD,
17 as having vascular dementia (VaD), 62 as having mixed
dementia (MD), and 11 as having other types of dementia
(3 cases of dementia with Lewy bodies, two of Parkinson’s
disease with dementia, one case of Creutzfeld–Jacob disease,
one case of cortico-basal dementia, one of fronto-temporal
dementia, one of hydrocephaly with normal pressure, one
case of glioblastoma and one case of cerebral metastasis).
The ‘other types of dementia’ group was excluded from the
analysis due to its heterogeneity and small size.
For most of the factors considered, no significant
differences were found between patients with the various
types of dementia (Table 3). Patients in theVaDgroup tended
to be younger and to be taking larger numbers of different
classes of medication. They were more likely to be male (P =
0.002) and had the highest average Charlson comorbidity
score (P = <0.0001). The prevalence of hypertension,
peripheral vascular disease, stroke, cerebrovascular disease
and hyperlipidaemia (P = 0.033; 0.043; <0.0001; <0.0001;
<0.0001, respectively) were higher in this group of patients,
in which BMIwas also higher on admission (P = 0.026). The
prevalence of comorbid medical conditions did not differ
significantly (P = 0.173) between patients with mild (mean
4.37 ± 2.4), moderate (mean 5.3 ± 3.0) and severe (mean
4.55 ± 2.1) dementia.
Discussion
This series of elderly inpatients (mean age of 85 years)
was found to be representative of the overall population
hospitalised in a geriatric ward. The prevalence of dementia
(44%) was very high. The reported prevalence of dementia
in elderly inpatients (geriatric acute wards) varies between
20 and 30%. A previous study in the same hospital
6 years ago reported a prevalence of 30%. This difference
is statistically significant (P = 0.000) [24]. These findings
probably reflect the systematic and complete assessment
of cognitive impairment in the random sample used to
determine dementia prevalence. The rate of refusal to
participate in this studywas very low (15%).Thehomogeneity
Table 1. Demographic data and clinical features of the patients included in this study, excluded patients and patients
who refused to participate in the study. Demographic data and functionality scores for the included patients and for all
patients admitted to the HOGER during 2004
Study cohort Excluded Refused All patients admitted P-valuec P-valueb
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Number of patients 349 49 61 1,473
Agea
Total 85.2 ± 6.7 84.0 ± 8.7 85.5 ± 7.2 84.5 ± 7.1 0.075 0.413
Female 85.6 ± 6.4 85.6 ± 8.1 86.6 ± 5.7 85.0 ± 7.1 0.206 0.648
Male 84.1 ± 7.6 80.4 ± 5.1 82.5 ± 6.6 83.2 ± 7.1 0.265 0.276
Femaleb 265 (76) 34 (69) 44 (72) 1,071 (72) 0.221 0.542
Length of stay [days]a 48.8(31) ± 53.1(38) 65.6 (41) ±74.4 (62) 40.1 (27) ±38.5 (39) 40.6 ± 39.4 0.482 0.152
FIMa 86.0(88) ± 26.1(41) 65.7 (64) ±26.3 (37) 86.1 (91) ±27.1 (42) 82.2 ± 27.6 0.006 0.000
a Data are expressed as means ± SD (median–IQR), b number of cases (%).
b P-value for Mann–Whitney U test comparing two groups (study cohort versus all patients admitted).
c P-value for Kruskal–Wallis test comparing three groups (study cohort versus excluded and refused patients).
FIM, Functional independence measure at admission.
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Table 2. Socio-demographic data, clinical features, hospitalisation correlates and outcomes as a
function of cognitive impairment diagnosis
Demented MCI Non-demented
Characteristics n = 151 n = 37 n = 161 p-valuec
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographics and pre-admission characteristics
Agea 85.60 6.47 85.90 6.42 84.80 7.03 0.498
Femaleb 111 73.5% 33 89.2% 121 75.2% 0.129
Education (years)b
Level 1 86 57.0% 24 66.7% 101 63.1% 0.568
Level 2 51 33.8% 8 22.2% 48 30.0%
Level 3 14 9.3% 4 11.1% 11 6.9%
Living conditionsb
Alone 74 49.7% 19 52.8% 104 65.0% 0.005
With family 12 8.1% 4 11.1% 10 6.3%
With spouse 39 26.2% 7 19.4% 35 21.9%
Nursing home 16 10.7% 1 2.8% 2 1.3%
In protected housing 8 5.4% 5 13.9% 9 5.6%
Cigarette smokingb 43 28.5% 15 40.5% 52 32.3% 0.352
Cigarette smokinga [packs/year] 18.37 21.97 16.65 25.69 18.97 25.35 0.977
Alcohol intakeb 64 42.4% 12 32.4% 77 47.8% 0.210
Alcohol intakea [glasses/day] 1.23 1.12 1.38 1.54 1.78 2.75 0.950
Functional statusa
Pre-morbid ADL 4.43 1.34 5.06 1.12 5.23 0.90 <0.0001
Pre-morbid IADL 3.27 2.23 4.83 1.90 5.30 2.00 <0.0001
Number of different classes of medicationa 2.58 1.30 2.19 1.02 2.20 1.15 0.009
Comorbid conditions
CCIa 4.87 2.56 3.97 2.70 4.50 2.79 0.154
Diseases assessed in the CCI
Ischaemic cardiopathyb 41 27.2% 13 35.1% 50 31.1% 0.568
Heart failureb 80 53.0% 24 64.9% 86 53.4% 0.403
Peripheral vascular diseaseb 53 35.1% 9 24.3% 67 41.6% 0.119
Cerebrovascular diseaseb 73 48.3% 7 18.9% 39 24.2% 0.000
Chronic pulmonary diseaseb 25 16.6% 8 21.6% 36 22.4% 0.418
Connective tissue diseaseb 15 9.9% 4 10.8% 21 13.0% 0.684
Ulcer diseaseb 23 15.2% 9 24.3% 35 21.7% 0.243
Diabetes mellitusb 29 19.2% 6 16.2% 35 21.7% 0.707
Chronic renal failureb 48 31.8% 10 27.0% 59 36.7% 0.447
Diabetes (end organ damage)b 6 4.0% 3 8.1% 10 6.2% 0.515
Any tumourb 44 29.1% 13 35.1% 53 32.9% 0.682
Cirrhosisb 5 3.3% 1 2.7% 6 3.7% 0.947
Other diseases not assessed in the CCI
Hypertensionb 101 66.9% 19 51.4% 117 72.7% 0.041
Atrial fibrillationb 40 26.5% 10 27.0% 37 23.0% 0.737
Stroke 33 21.9% 4 10.8% 20 12.4% 0.050
Hypercholesterolaemiab 24 15.9% 6 16.2% 26 16.2% 0.998
Assessment at admission
FIMa 77.32 25.89 86.69 24.72 93.48 24.98 0.000
BMIa 23.30 4.81 24.12 5.07 24.76 5.10 0.026
MNAa 8.51 2.85 8.89 3.09 9.70 2.86 0.001
Assessment at discharge
FIMa 84.87 27.88 107.40 16.62 99.56 28.81 <0.0001
BMIa 22.83 5.04 24.13 4.91 24.06 5.38 0.069
a Data are expressed as means ± SD.
b Number of cases (%).
c P-value of Kruskal–Wallis test or ANOVA comparing three groups.
Education level: (level 1 = ≤ 11; level 2 = 12–14; level 3 ≥15 years of schooling). ADL = Activities of Daily Living [14], IADL,
Lawton’s Instrumental Activities of Daily Living [15]; CCI, The Charlson Comorbidity Index [19]; FIM, Functional independence
measure [20]; BMI, body mass index; MNA, Mini Nutritional Assessment [21].
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Table 3. Socio-demographic data, clinical features, hospitalisation correlates and outcomes as a function
of dementia aetiology (11 cases with other types of dementia are not shown)
Alzheimer’s disease Mixed dementia Vascular dementia
Characteristics n = 61 n = 62 n = 17 P-valuec
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographics and pre-admission characteristics
Agea 86.1 6.0 86.4 5.4 84.3 7.5 0.452
Femaleb 51 83.6% 45 72.6% 7 41.2% 0.002
Education (years)b
Level 1 39 63.9% 32 51.6% 10 58.8% 0.435
Level 2 15 24.6% 25 40.3% 6 35.3%
Level 3 7 11.5% 5 8.1% 1 5.9%
Living conditionsb
Alone 33 54.1% 32 52.5% 6 37.5% 0.888
With family 3 4.9% 6 9.8% 1 6.3%
With spouse 15 24.6% 14 23.0% 6 37.5%
Nursing home 6 9.8% 7 11.5% 2 12.5%
In protected housing 4 6.6% 2 3.3% 1 6.3%
Cigarette smokingb 17 27.9% 19 30.7% 7 41.2% 0.575
Cigarette smokinga [packs/year] 17.77 21.27 20.09 24.36 23.36 18.96 0.554
Alcohol intakeb 27 44.3% 30 48.4% 4 23.5% 0.185
Alcohol intakea [glasses/day] 1.16 1.03 1.53 1.25 1.00 1.00 0.337
Functional statusa
Pre-morbid ADL 4.70 1.26 4.47 1.20 4.00 1.62 0.218
Pre-morbid IADL 3.66 2.30 3.29 2.17 2.53 2.27 0.195
MMSEa 16.3 4.7 15.6 4.9 17.5 6.7 0.3656
CDR 0.5b 1 1.6% 1 1.6% 1 5.9% 0.612
CDR 1b 27 44.3% 25 40.3% 9 52.9%
CDR 2b 26 42.6% 28 45.2% 4 23.5%
CDR 3b 7 11.5% 8 12.9% 3 17.7%
Number of different classes of medicationa 2.28 1.27 2.73 1.24 3.00 1.17 0.067
Comorbid conditions
CCIa 4.18 2.49 5.11 2.33 6.35 2.55 <0.0001
Diseases assessed in the CCI
Ischaemic cardiopathyb 14 23.0% 20 32.3% 7 41.2% 0.272
Heart failureb 28 45.9% 37 59.7% 12 70.6% 0.119
Peripheral vascular diseaseb 20 32.8% 21 33.9% 11 64.7% 0.043
Cerebrovascular diseaseb 14 23.0% 36 58.1% 16 94.1% <0.0001
Chronic pulmonary diseaseb 10 16.4% 9 14.5% 5 29.4% 0.345
Connective tissue diseaseb 10 16.4% 5 8.1% 0 0.0% 0.103
Ulcer diseaseb 10 16.4% 12 19.4% 1 5.9% 0.414
Diabetes mellitusb 8 13.1% 13 21.0% 4 23.5% 0.424
Chronic renal failureb 8 13.1% 13 21.0% 4 23.5% 0.424
Diabetes (end organ damage)b 3 4.9% 1 1.6% 1 5.9% 0.529
Any tumourb 16 26.2% 21 33.9% 3 17.8% 0.366
Cirrhosisb 2 3.3% 2 3.2% 0 0.0% 0.752
Other diseases not assessed in the CCI
Hypertensionb 37 60.7% 41 66.1% 16 94.1% 0.033
Atrial fibrillationb 12 19.7% 21 33.9% 4 23.5% 0.195
Strokeb 4 6.6% 16 25.8% 11 64.7% <0.0001
Hypercholesterolaemiab 5 8.2% 8 12.9% 9 52.9% <0.0001
Assessment at admission
FIMa 78.83 25.51 76.24 26.20 78.13 27.11 0.887
BMIa 23.24 4.40 22.50 4.62 26.05 6.15 0.026
MNAa 8.64 2.42 8.29 3.14 9.06 3.43 0.521
Assessment at discharge
FIMa 89.56 24.19 80.34 31.02 88.60 22.66 0.498
BMIa 22.17 5.30 22.66 4.46 25.81 6.05 0.081
aData are expressed as means ± SD.
bNumber of cases (%).
cP-value for Kruskal–Wallis test, or ANOVA, comparing three groups.
ADL, Activities of Daily Living [14], IADL, Lawton’s Instrumental Activities of Daily Living [15],
MMSE, The Mini Mental State Examination (scores 0–30) [12]; CDR, The Clinical Dementia Rating Scale [23]
(score 0.5 for MCI, score 1 for mild, score 2 for moderate and score 3 for severe dementia); CCI, The Charlson Comorbidity Index [19];
FIM, Functional independence measure [20]; BMI, body mass index; MNA, Mini Nutritional Assessment [21].
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of the group of patients studied and the group consisting
of all the patients admitted to the HOGER in the same
year shows that our sample was representative of the total
population of patients admitted and highlights the quality of
randomisation in this study. The principal strength of this
study is its clinically rich prospective data collection from
a large group of very ill hospitalised elderly patients. The
comorbidity index was much higher (mean 4.6 ± 2.7) than
reported in other studies [7, 11]. The second major strength
of this study is that the same neuropsychologist carried out
a systematic, complete neuropsychological assessment of all
the included patients, increasing the accuracy of cognitive
diagnosis. This is the first study of its type to consider a
group of patients with MCI in addition to demented and
non-demented patients.
In line with increasing numbers of reports, the functional
and nutritional status of demented patients was significantly
worse than that of the other patients at both admission
and discharge, regardless of the type of dementia. In
a cohort of 830 Italian patients aged 65 years or older
consecutively admitted to an acute care geriatric ward, and
in a cohort of 1,358 Japanese subjects aged 61 years or
older living in the community, poor cognitive status was
independently associated with functional disability at all
ages [25, 26].
In our series, the prevalence of comorbid medical
conditions was similar in demented patients, patients with
MCI and patients of the same age with no cognitive
impairment, but demented patients took larger amounts
of medication. Some studies have reported the occurrence of
larger numbers of comorbidmedical conditions in cognitively
normal old subjects [1–5]. One study of elderly subjects
living in their own homes showed that patients with AD
had fewer medical diagnoses—three in this cohort—than
subjects without cognitive impairment [1]. Similar results
were obtained in a French geriatric hospital that also showed,
in contrast to our results, that patients with dementia took
fewer drugs than non-demented subjects, and that they took
different kinds of drugs, with more psychotropes and fewer
cardiovascular drugs than non-demented patients [2]. Most
of these studies were retrospective [1, 2, 4]. More recent
population-based prospective studies have shown, as in
this study, that missed diagnoses are more common in
patients with dementia and that these patients complain
almost exclusively of cognitive impairment. One such study
showed that 66% of the 112 demented patients included had
at least one undiagnosed disease, versus only 48%of the non-
demented patients [8]. The demented patients were more
likely than the controls to have undiagnosed hyperlipidaemia
or hypothyroidism. In another study of patients in the
early stages of AD, identical CCI values were obtained
for demented and non-demented subjects but, over the
two years of follow-up, patients with dementia complained
almost exclusively of cognitive impairment whereas the
controls also complained of joint pains, gastrointestinal
problems and vision loss [7]. A large retrospective study
of 3,934 patients with dementia and 19,300 control subjects
matched for sex and age enrolled in a large Medicare-
managed care organisation showed that demented patients
had significantly larger numbers of comorbid conditions
(mean CCI = 1.9) than patients without dementia (mean
CCI = 1.0). For congestive heart failure and cerebrovascular
disease, major differences have been reported [11]. This
cohort was younger (mean age = 78 years) and the
percentage of women (60%) was much closer to that
of men.
According to the most recent studies, the number of
comorbid conditions seems to be similar in demented
and non-demented subjects, but some studies have shown
differences in the prevalence of particular diseases. For
example, cancer has been reported to be more prevalent in
non-demented subjects than in demented subjects in clinical
and autopsy series [1, 2, 27, 28].
There may also be differences in the prevalence of co-
existing medical conditions between the various types of
dementia andbetweendifferent levels of severity of dementia.
We found that health was poorest in the VaD group: highest
average comorbidity score, higher frequency of hypertension,
peripheral vascular disease, stroke, cerebrovascular disease,
hyperlipidaemia and a higher BMI on admission, probably
associated with these patients being overweight. These
findings are consistent with previous studies [2, 6, 29]. In
contrast, Doraiswamy et al. showed in a cross-sectional study
including 679 AD patients from the community and nursing
homes that medical comorbidity increased with severity of
dementia [30]. However, most of the patients with mild
dementia were living at home, whereas those with severe
dementia were up to 10 years older and lived in nursing
homes.
Our results show that hospitalised demented patients have
a poorer functional and nutritional status than cognitively
normal patients of the same age. They also seem to
have more other illnesses than generally thought, but
these illnesses are more likely to remain undiagnosed
and thus untreated. Special efforts should be made to
investigate existing comorbidities and to detect unreported
problems in demented patients, with the development of
screening strategies for detecting comorbid conditions in
demented patients. Improving the detection and treatment
of comorbid diseases represents a challenge for health
professionals caring for patients with dementia. Greater
attention to these complex issues on the part of families,
carers and clinicians should improve outcomes for these
patients.
Key points
• In this prospective cohort of very old inpatients, demented
patients, non-demented patients and patients with MCI
had similar levels of comorbidity. However, demented
patients had poorer functional and nutritional status.
Health was poorest in patients with VaD.
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• Special efforts should be made to deal with existing
comorbidities and to detect unreported problems in
demented patients. Improvements in the detection and
treatment of comorbid diseases should improve outcomes
for these patients.
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